E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
12 / 02 / 2023

 


Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center

Bharath Kathi, Vubbara Anupama, A Udaya Kiran, Balaji Patamsetty, Gorthi Aruna, Subbarao Singapati, M Neethi Chandra, Visweswara Rao Guthi.


Abstract
Background: Extensively drug-resistant tuberculosis (XDR TB) is a type of tuberculosis (TB) characterized by resistance to isoniazid and rifampicin, along with resistance to one of the fluoroquinolones and at least one of the second line injectable drugs. Bedaquiline is a diarylquinoline antimycobacterial agent approved for the treatment of adults with pulmonary multidrug-resistant TB (MDR-TB) and XDR-TB by the food and drug administration.

Aim and Objective: The aim of this study was to study the side effect profile of bedaquiline containing regimen among XDR TB patients.

Materials and Methods: This study was conducted at outpatient and wards of nodal drug-resistant TB Center, Department of Pulmonary Medicine, SVRRGGH, Tirupati, for a period of 1 year. Forty patients of more than 18 years age and diagnosed with XDR TB were included in the study. Bedaquiline was started and daily monitoring was done with ECG and all organ function tests were repeated every 15 days.

Results: All 40 cases were retreatment cases; no new XDR TB case was reported in study period. Most common age group of presentation in our study was 46 to 55 years (32.5%). Gastrointestinal adverse drug reactions were found to be more common (37.5%), cardiovascular QTc changes were observed in 10% of patients, 5% of patients had neurological reactions (Headache), 2.5% of patients had peripheral neuropathy, and 2.5% of patients had arthralgia.

Conclusions: Bedaquiline containing regimen is very effective for the treatment of XDR TB cases. The study shows that compliance with this regimen is very good. Bedaquiline has minimal adverse reactions and even these are easily manageable. Bedaquiline has good safety profile and patients have improved quality of life.

Key words: Extensively Drug-Resistant Tuberculosis; Bedaquiline; Side Effects; Nodal Drug-resistant TB Center


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Bharath Kathi
Articles by Vubbara Anupama
Articles by A Udaya Kiran
Articles by Balaji Patamsetty
Articles by Gorthi Aruna
Articles by Subbarao Singapati
Articles by M Neethi Chandra
Articles by Visweswara Rao Guthi
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Kathi B, Anupama V, Kiran AU, Patamsetty B, Aruna G, Singapati S, Chandra MN, Guthi VR. Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. Natl J Physiol Pharm Pharmacol. 2023; 13(3): 648-651. doi:10.5455/njppp.2023.13.02057202306022023


Web Style

Kathi B, Anupama V, Kiran AU, Patamsetty B, Aruna G, Singapati S, Chandra MN, Guthi VR. Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. https://www.njppp.com/?mno=142371 [Access: March 14, 2024]. doi:10.5455/njppp.2023.13.02057202306022023


AMA (American Medical Association) Style

Kathi B, Anupama V, Kiran AU, Patamsetty B, Aruna G, Singapati S, Chandra MN, Guthi VR. Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. Natl J Physiol Pharm Pharmacol. 2023; 13(3): 648-651. doi:10.5455/njppp.2023.13.02057202306022023



Vancouver/ICMJE Style

Kathi B, Anupama V, Kiran AU, Patamsetty B, Aruna G, Singapati S, Chandra MN, Guthi VR. Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. Natl J Physiol Pharm Pharmacol. (2023), [cited March 14, 2024]; 13(3): 648-651. doi:10.5455/njppp.2023.13.02057202306022023



Harvard Style

Kathi, B., Anupama, . V., Kiran, . A. U., Patamsetty, . B., Aruna, . G., Singapati, . S., Chandra, . M. N. & Guthi, . V. R. (2023) Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. Natl J Physiol Pharm Pharmacol, 13 (3), 648-651. doi:10.5455/njppp.2023.13.02057202306022023



Turabian Style

Kathi, Bharath, Vubbara Anupama, A Udaya Kiran, Balaji Patamsetty, Gorthi Aruna, Subbarao Singapati, M Neethi Chandra, and Visweswara Rao Guthi. 2023. Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. National Journal of Physiology, Pharmacy and Pharmacology, 13 (3), 648-651. doi:10.5455/njppp.2023.13.02057202306022023



Chicago Style

Kathi, Bharath, Vubbara Anupama, A Udaya Kiran, Balaji Patamsetty, Gorthi Aruna, Subbarao Singapati, M Neethi Chandra, and Visweswara Rao Guthi. "Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 648-651. doi:10.5455/njppp.2023.13.02057202306022023



MLA (The Modern Language Association) Style

Kathi, Bharath, Vubbara Anupama, A Udaya Kiran, Balaji Patamsetty, Gorthi Aruna, Subbarao Singapati, M Neethi Chandra, and Visweswara Rao Guthi. "Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center." National Journal of Physiology, Pharmacy and Pharmacology 13.3 (2023), 648-651. Print. doi:10.5455/njppp.2023.13.02057202306022023



APA (American Psychological Association) Style

Kathi, B., Anupama, . V., Kiran, . A. U., Patamsetty, . B., Aruna, . G., Singapati, . S., Chandra, . M. N. & Guthi, . V. R. (2023) Study of side effect profile of bedaquiline containing regimen among patients with extensively drug-resistant tuberculosis at a nodal drug-resistant center. National Journal of Physiology, Pharmacy and Pharmacology, 13 (3), 648-651. doi:10.5455/njppp.2023.13.02057202306022023